News

Dr. Reddy`s Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy`s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy`s readiness to ensure patient access following approval.In Canada, Dr. Reddy`s Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.

Net profit of Dr Reddy`s Laboratories declined 86.14% to Rs 220.90 crore in the quarter ended March 2026 as against Rs 1593.30 crore during the previous quarter ended March 2025. Sales declined 11.64% to Rs 7516.20 crore in the quarter ended March 2026 as against Rs 8506.00 crore during the previous quarter ended March 2025.For the full year,net profit declined 25.80% to Rs 4196.00 crore in the year ended March 2026 as against Rs 5655.10 crore during the previous year ended March 2025. Sales rose 3.19% to Rs 33593.30 crore in the year ended March 2026 as against Rs 32553.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7516.208506.00 -12 33593.3032553.50 3 OPM %5.0923.49 -19.2126.26 - PBDT756.802459.90 -69 7451.509383.20 -21 PBT199.702005.20 -90 5392.707679.50 -30 NP220.901593.30 -86 4196.005655.10 -26 Powered by Capital Market - Live News

Dr Reddys Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 23 July 2026.

Dr Reddys Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, has recommended a Final Dividend of Rs.8 per share (i.e.800%), subject to the approval of the shareholders.

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2026.Powered by Capital Market - Live News